Hematopoietic and Lymphatic System NeoplasmNCT07456436
Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials
An observational study of Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by University of Southern California at 1 site in United States.
Trial summary
This study assesses patient awareness and understanding of cancer clinical trials. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Non-Interventional Study
- How many people
- 111 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Nov 2024to 23 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals with cancer in the Norris Comprehensive Cancer Center (NCCC) catchment area.
Who may be able to join
- Eligible patient participants will be:
- Black/African American, Asian/Asian American, White or Hispanic adults of any gender 21 years of age or older. Race/ethnicity will be self-reported
- Have been diagnosed any cancer type
Who cannot join
- Participants (patients) will be excluded if they:
- Are unable to give informed consent
- Are unable to speak English or Spanish
Trial locations and contacts
1 site in 1 country.
United States1 site
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
About this study
This study assesses patient awareness and understanding of cancer clinical trials.
Read the detailed description
PRIMARY OBJECTIVE:
- To develop a multi-level data-driven intervention to improve cancer patient engagement with cancer clinical trials.
OUTLINE: This is an observational study.
Patients review educational materials and complete surveys on study.
- Being tested
- Non-Interventional Study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-Interventional StudyOther
Also called Non-Interventional Observational Study, Noninterventional (Observational) Study
Non-interventional study
| Study group | Role | What they receive |
|---|---|---|
| Observational | Patients review educational materials and complete surveys on study. Receives: Other: Non-Interventional Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Baseline Survey Score
The survey is a validated instrument (CHEKS*) evaluated patients' knowledge and beliefs about cancer clinical trials (CCTs) before and after exposure to educational stimuli (written and video) detailing the purpose and characteristics of CCTs. The survey scores knowledge and beliefs about CCTs on a 100-point scale.The survey is collected before and after education materials are provided. The change in survey score will be analyzed. A paired t-test will be used to examine changes in CCT knowledge and Chi-Square tests of association to determine whether CCT knowledge and beliefs are associated with sociodemographic variables.
*Chung A, Donley T, Hays RD, et al. Development and evaluation of the Clinical Trial HEalth Knowledge and Beliefs Scale (CHEKS). Int J Environ Res Public Health. 2022;19(14):8660. doi:10.3390/ijerph19148660
Measured: Through study completion, up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start26 Nov 2024
- Primary completion23 Jul 2026
- Study completion23 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphatic System NeoplasmStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 111 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Merck Sharp & Dohme LLC
- Responsible party
- Sponsor
- Investigators
- Chanita Hughes-Halbert, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07456436
- Sponsor's protocol ID
- 19PS-24-2
- Other IDs
- NCI-2026-00806, 19PS-24-2, P30CA014089
- Status last verified
- Aug 2026
- First submitted
- 20 Feb 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials
- ClinicalTrials.gov ID
- NCT07456436
- Acronym / sponsor ID
- 19PS-24-2
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 111 participants (actual)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Merck Sharp & Dohme LLC
- Study start
- 26 Nov 2024 (actual)
- Primary completion
- 23 Jul 2026 (actual)
- Study completion
- 23 Jul 2027 (estimated)
- First posted
- 6 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study assesses patient awareness and understanding of cancer clinical trials.
Detailed description
PRIMARY OBJECTIVE:
- To develop a multi-level data-driven intervention to improve cancer patient engagement with cancer clinical trials.
OUTLINE: This is an observational study.
Patients review educational materials and complete surveys on study.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational | – | Other: Non-Interventional StudyPatients review educational materials and complete surveys on study. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals with cancer in the Norris Comprehensive Cancer Center (NCCC) catchment area.
Key inclusion criteria (3 listed)
- Eligible patient participants will be:
Key exclusion criteria (3 listed)
- Participants (patients) will be excluded if they:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-Interventional StudyAlso: Non-Interventional Observational Study, Noninterventional (Observational) StudyNon-interventional study | Other | Observational |
Primary outcome
Change in Baseline Survey Score
Time frame: Through study completion, up to 1 year
The survey is a validated instrument (CHEKS*) evaluated patients' knowledge and beliefs about cancer clinical trials (CCTs) before and after exposure to educational stimuli (written and video) detailing the purpose and characteristics of CCTs. The survey scores knowledge and beliefs about CCTs on a 100-point scale.The survey is collected before and after education materials are provided. The change in survey score will be analyzed. A paired t-test will be used to examine changes in CCT knowledge and Chi-Square tests of association to determine whether CCT knowledge and beliefs are associated with sociodemographic variables. *Chung A, Donley T, Hays RD, et al. Development and evaluation of the Clinical Trial HEalth Knowledge and Beliefs Scale (CHEKS). Int J Environ Res Public Health. 2022;19(14):8660. doi:10.3390/ijerph19148660
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
Related trials for Hematopoietic and Lymphatic System Neoplasm
Recruiting
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chanita Hughes-Halbert principal investigator
University of Southern California
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, run by University of Southern California at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Baseline Survey Score (time frame: Through study completion, up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.